Clinical trials: Chemoradiation
Head and Neck Cancer
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas.
- Trial name
- NCT00228488
- Testing
- Gefitinib
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Oral Mucositis
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers.
- Trial name
- KEVLARx (NCT05966194)
- Testing
- RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
- Where
- 14 sites in United States
- Volunteers
- 216 people
- Sponsor
- EpicentRx, Inc.
Esophageal Squamous Cell Carcinoma
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to…
- Trial name
- SKYSCRAPER-07 (NCT04543617)
- Testing
- Tiragolumab, Atezolizumab
- Where
- 166 sites in United States, Argentina and 26 more
- Volunteers
- 760 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Adenocarcinoma
A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer
The primary objective of this study is to assess the efficacy of nimotuzumab in combination with chemotherapy and radiotherapy for the treatment of locally advanced esophageal cancer, comparing it to that of the conventional…
- Trial name
- NICE (NCT01249352)
- Testing
- Nimotuzumab, Cisplatin, Fluorouracil
- Where
- 19 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- Eurofarma Laboratorios S.A.
Glioblastoma, Gliosarcoma
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly…
- Trial name
- Intellance1 (NCT02573324)
- Testing
- Temozolomide, Depatuxizumab mafodotin, Radiation
- Where
- 212 sites in United States, Argentina and 26 more
- Volunteers
- 691 people
- Sponsor
- AbbVie
Locally Advanced Resectable Rectal Cancer
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.
- Trial name
- NCT07454720
- Testing
- Adebrelimab in combination with SHR-8068 and chemotherapy, Adebrelimab combined with chemotherapy, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 165 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Small Cell Lung Cancer
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed…
- Trial name
- AK112-311 (NCT07010263)
- Testing
- AK112
- Where
- 53 sites in China
- Volunteers
- 560 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.
- Trial name
- NCT00960115
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Saline
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Urothelial Cancer, Urinary Bladder Neoplasms
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer.
- Trial name
- NCT07566156
- Testing
- Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy
- Where
- 26 sites in United States, Canada and 2 more
- Volunteers
- 390 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Carcinoma, Squamous Cell
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Primary objective: To assess the response rate to induction therapy with docetaxel/CDDP. Secondary objectives: To assess Resectability after induction therapy Time to progression Overall survival Safety profile Quality of Life
- Trial name
- NCT00432315
- Testing
- Docetaxel + CDDP
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer Stage III
A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in patients with unresectable EGFR-mutated Stage III non-small…
- Trial name
- NCT07640789
- Testing
- BL-B01D1, Osimertinib
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced Rectal Cancer (LARC)
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor…
- Trial name
- FORTRESS (NCT06459869)
- Testing
- NG-350A IV administration, Capecitabine oral administration, Radiotherapy
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Akamis Bio
Glioblastoma Multiforme
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM).
- Trial name
- NCT01280552
- Testing
- ICT-107
- Where
- 25 sites in United States
- Volunteers
- 124 people
- Sponsor
- Precision Life Sciences Group
Non-small Cell Lung Cancer
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant…
- Trial name
- MDT-BRIDGE (NCT05925530)
- Testing
- Durvalumab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
Head and Neck Cancer
Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients
The goal of this observational study is to assess the satisfaction and usability of an interactive and patient-centered mobile application (app), Oleena™, designed to assist head and neck cancer patients undergoing chemoradiation…
- Trial name
- SYMTECH01 (NCT06385587)
- Testing
- Oleena
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Aptar Digital Health
Cancer-related Fatigue, Survival
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
The primary objective of this study is to evaluate the efficacy of PG2 concurrent with concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced esophageal cancer patients who are under preoperative…
- Conditions
- Cancer-related Fatigue, Survival, Tumor, Esophageal
- Trial name
- NCT03611712
- Testing
- Astragalus Polysaccharides 500 mg
- Where
- 4 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- PhytoHealth Corporation
Non-Small Cell Lung Cancer
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC]…
- Trial name
- NCT03519971
- Testing
- Durvalumab, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel
- Where
- 86 sites in Brazil, Czechia and 12 more
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
In the RELEVANCE study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage III NSCLC population in Canada across several Canadian cancer centres.
- Trial name
- RELEVANCE (NCT05933044)
- Testing
- Durvalumab
- Where
- 5 sites in Canada
- Volunteers
- 662 people
- Sponsor
- AstraZeneca
Locally Advanced Cervical Carcinoma
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer
- Trial name
- AK104-305 (NCT05235516)
- Testing
- AK104, EBRT, BT
- Where
- 9 sites in China
- Volunteers
- 636 people
- Sponsor
- Akeso